zylidacbio.comCrawled Nov 13, 2026
Meet Zylidac, a new biologics CDMO. Read a Q&A with its leaders on the team's 40+ years of experience, from development to commercial manufacturing.
Zylidac Bio and Prolific Machines partner to scale an optogenetics-enabled biologics manufacturing platform from development through GMP production.
Integrated biopharmaceutical CDMO offering cell line development, upstream/downstream manufacturing, formulation, analytical testing & fill-finish services.
Zylidac Bio LLC’s website includes a disclaimer and privacy policy covering terms of use, personal information practices, and privacy choices.
Zylidac Bio LLC explains how it collects, uses, and shares consumer health data under Washington’s My Health My Data Act, including user rights.
Zylidac Bio LLC outlines its efforts to combat slavery and human trafficking in its supply chain, including supplier screening, accountability measures, and training.
Zylidac Bio LLC provides an accessibility statement detailing its efforts and instructions for reporting issues or requesting help with its website.
Zylidac Bio evaluates whether optogenetic cell lines—achieving 21 g/L yields in small-scale CHO runs—can maintain high productivity for complex biologics at **Good Manufacturing Practice (GMP) scale**. The company assesses whether the platform’s efficiency translates to large-scale manufacturing while preserving biologic quality. Prolific’s technology enables precise light-controlled gene expression, potentially improving protein production consistency.
Zylidac Bio and Prolific Machines collaborate to advance Prolific’s light-controlled cell line platform into **GMP-compliant manufacturing**. The partnership leverages Zylidac’s Emeryville facility to transition the technology—aimed at improving yield, precision, and quality for complex biologics—from lab-scale development to full production. Prolific’s platform targets next-generation biologics manufacturing with enhanced control mechanisms.
Zylidac Biologics, a CDMO subsidiary of Zydus Lifesciences, operates a facility in Emeryville, CA, offering end-to-end biologics development and manufacturing. The team brings over four decades of experience in producing antibodies, bispecifics, and fusion proteins from preclinical stages to commercial distribution. Services include cell-line development, fill/finish, labeling, packaging, and logistics support for clients.
Zydus acquires two of Agenus’ manufacturing sites as part of a **$141 million** deal to strengthen its oncology drug production platform. The agreement includes manufacturing support for Agenus’ pipeline while expanding Zydus’ capabilities in bioprocessing for cancer therapies. Both companies collaborate on joint development and supply-chain integration for next-generation oncology treatments.
Zydus Lifesciences acquires Agenus Inc.’s biologics manufacturing facilities and launches **Zylidac Bio LLC** in the U.S. The deal includes an asset purchase, share purchase, and exclusive licensing agreement, expanding Zydus’s global biologics production capacity. The transaction follows regulatory approvals and strengthens Zydus’s presence in the American biopharmaceutical market.
Zydus plans to acquire Agenus’ U.S. biologics manufacturing facilities to expand into the global contract development and manufacturing organization (CDMO) market. The move strengthens Zydus’ ability to support innovative biotechnology firms with advanced biologics development and production services. The acquisition targets the rapidly growing biologics CDMO sector.

Zylidac Bio guides molecules from cell line development through commercial manufacturing and packaging at one site for biologics clients.